Contraceptive Technology Update – November 1, 2005
November 1, 2005
View Issues
-
Patch and ring make inroads on birth control pill’s popularity
As you review the list of contraceptive options available at your family planning facility with your next female patient, which one most likely will receive the nod from her? -
Pill power: Clinicians speak out on OC choices
The young woman sitting in front of you is in good health and says she would like to use a birth control pill. Which pill do you prescribe? -
How to use OCs? Readers share pill strategies
As you check the chart of a new patient, you note that she has previously experienced nausea on birth control pills, but cant remember the brand name of her prescribed oral contraceptive (OC). She would like to re-establish pill use. Which OC will you suggest? -
Intrauterine method sees upswing in use
More women are choosing long-term birth control through use of intrauterine contraception, say participants in the 2005 Contraceptive Technology Update Contraception Survey. -
DMPA: Survey offers snapshot of shot use
Rewind to November 2004: the Food and Drug Administration (FDA) announces the addition of a black box warning to the labeling for the injectable contraceptive depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer, New York City and MedroxyPROGESTERone Injection, Teva Pharmaceuticals USA, North Wales, PA). -
Washington Watch: FDA fails to rule on EC OTC status . . . again
On Aug. 26, the U.S. Food and Drug Administration (FDA) announced that it would indefinitely postpone its decision to allow nonprescription status for the emergency contraceptive pill Plan B popularly known as the morning-after pill.